• Mashup Score: 0
    Low-dose DOACs in SVT - 1 year(s) ago

    Implied Consent Form Study Title: Extended anticoagulation for secondary prevention of recurrent venous thromboembolism using low-dose direct oral anticoagulants in patients with splanchnic vein thrombosis. An international practice of thrombosis specialists. Principal Investigator: Dr. Aurélien Delluc, Division of Hematology at The Ottawa Hospital; Phone: 613-737-8899 extension 71069; Fax:…

    Tweet Tweets with this article
    • Honored to collaborate with Dr. Ageno & @NicolettaRivaMD @DellucAurelien @MarcCarrier1 @MarcelloDiNisio @LaurentBertole1 @CukerMd on this low-dose #DOAC for splanchnic vein #thrombosis study. Please help us by completing this survey: https://t.co/1tTdbNnOJE #ISTH SSC grant https://t.co/bfyBREjhi1

  • Mashup Score: 0

    A vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, appears to be a better treatment for patients with thrombotic antiphospholipid syndrome, a new meta-analysis suggests.

    Tweet Tweets with this article
    • #Warfarin best for thrombotic #AntiphospholipidSyndrome? 👉https://t.co/uNkSRVr1Su @MDEdgeHemOnc @Hughesedits4u #DOAC https://t.co/3fAZaTyy3v

  • Mashup Score: 4

    Patients with thrombotic antiphospholipid syndrome appear better treated with a vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, a new meta-analysis suggests.

    Tweet Tweets with this article
    • A new systematic review in #JACC suggests that patients w/ thrombotic antiphospholipid syndrome should be treated with a vitamin K antagonist, such as warfarin, instead of a #DOAC. @SueHughes8 explores the new findings in @Medscape: https://t.co/OZO1VH5XFV #cvCoag